Savana Medica Raises $15M to Expand AI Clinical Note Analysis to the US

Savana, a service utilizing machine learning to convert physician and pharmacist clinical notes into organized patient data, has secured $15 million in funding to expand its operations from Spain into the United States, according to a company announcement.

Cathay Innovation spearheaded the funding round, with contributions from Seaya Ventures, a Spanish investment company that previously invested in Savana, and additional backing from new investors including MACSF, a French insurer specializing in coverage for medical professionals.

To date, the company has analyzed 400 million electronic health records in multiple languages, including English, Spanish, German, and French.

Established in Madrid in 2014, Savana is establishing a presence in New York and is currently collaborating with leading global pharmaceutical corporations and over 100 healthcare organizations.

“We are dedicated to forecasting disease onset on an individual patient basis. This directs our efforts toward developing innovative methods for delivering medical insights with near-instantaneous speed – a capability that is particularly critical given the current pandemic,” stated Jorge Tello, Savana’s CEO. “Global healthcare issues are becoming increasingly prevalent, and we firmly believe that the application of artificial intelligence to large-scale health data is vital for advancing medical science.”

Savana’s co-founder and Chief Medical Officer, Dr. Ignacio Hernandez Medrano, also highlighted the company’s commitment to data privacy while processing substantial volumes of electronic records.

“A key benefit we offer is maintaining hospital control over the information, ensuring patient confidentiality through the de-identification of data prior to analysis,” he explained.